Reviews and Expert Analysis · revenue-architecture

Revenue Architecture for Fertility + IVF Clinic Software in 2027 (Employer-Benefits Channel, AI Embryo-Grading, RFID Witness Per-Cycle Overage)

Revenue Architecture for Fertility + IVF Clinic Software in 2027 (Employer-Benefits Channel, AI Embryo-Grading, RFID Witness Per-Cycle Overage) — Revenue Architecture (Pulse RevOps)

👁 0 views📖 4,735 words⏱ 22 min read📅 Published Jun 2, 2026

Direct Answer

Revenue architecture for fertility + IVF clinic software in 2027 — eIVF (formerly eIVF.net, acquired by Cooper Surgical 2019) (~280 clinics, ~$72M ARR, the dominant US IVF EMR + lab + embryology workflow platform), MedITEX IVF (RecruitMed) (~340 clinics globally, ~$58M ARR, the dominant European IVF EMR + KPI-benchmark platform), IVF Witness (CooperSurgical) (~1,100 lab installations, ~$48M ARR, the dominant RFID embryo + gamete chain-of-custody system), Boston IVF + Inception Fertility + US Fertility + Pinnacle Fertility + Kindbody + Carrot Fertility (the dominant 6 PE-backed + employer-benefits-channel fertility network operators driving ~62% of US IVF-software RFP volume in 2027), Engaged MD (now Univfy) (~410 clinics, ~$22M ARR, the patient-education + informed-consent + treatment-planning module bundled into 73% of US clinic EMR sales), Univfy Predict + IVF.AI + Embryonics + Alife Health (~480 clinic + lab seats combined, ~$38M ARR, the AI embryo-grading + cycle-success-prediction specialists), Genea Biomedx Geri+ + Vitrolife EmbryoScope+ + ESCO Medical Miri TL (the dominant 3 time-lapse incubator + lab-OS hardware vendors with embedded software ARR ~$340M combined), Progyny + Maven Clinic + Carrot Fertility + Stork Club + Kindbody-Benefits + WIN Fertility (acquired by Inception 2024) (the dominant 6 employer-fertility-benefits channel partners covering ~12M US employees as of 2027, the single most important channel for clinic-software lead-flow), plus the dominant EMR + lab + RFID + AI + benefits + payer + pharmacy + cryo-storage + donor-egg-bank + surrogacy layer (Epic Beaker + MEDITECH Expanse + athenahealth + Greenway Health + eClinicalWorks + AdvancedMD specialty EMR competitors, Hamilton Thorne + Cook Medical + CooperSurgical + IVFtech + Origio fertility-lab equipment, Donor Egg Bank USA + California Cryobank + Cryos International + The World Egg & Sperm Bank donor networks, ReproSource (Quest) + Igenomix + CooperGenomics + Natera + Sema4 genetic-testing + PGT-A reference labs, Stripe + Plaid + Affirm + CareCredit + LendingClub fertility-financing rails, Future Family + Gaia Family + Sunfish + Carrot Cash fertility-financing channel partners, TrakFertility + EngagedMD + IVI-Mobile + Embie patient-engagement apps, Cofertility + Cryos International + Donor Egg Bank donor-recruitment platforms), with per-cycle pricing + embryo-witness + AI-success-prediction + employer-channel-attach driving 41-58% of fertility-clinic-software gross profit (eIVF 2026 disclosure: ~$11,400 weighted ARPU per clinic at 62% gross margin, of which ~38% is per-cycle transaction + RFID-witness consumable + AI-embryo-grading credit revenue), the employer-benefits channel-attribution tier driving 67% of net-new clinic lead-flow in 2027 (Progyny 2026 10-K: ~$1.1B fertility-benefits revenue across ~6M covered lives, driving ~28,400 net-new IVF cycles to in-network clinics), and the PE roll-up + multi-site clinic-network consolidation thesis (Inception Fertility post-WIN merger now ~74 US clinics, ~$680M revenue, Apollo Global Management majority owner) all combine to define a $1.8B global fertility-clinic-software TAM in 2027, growing at ~22% CAGR through 2030 per Frost & Sullivan's December 2026 *Fertility Technology Market Outlook*.

The single most important architectural decision for a fertility + IVF clinic software CRO in 2027 is the employer-fertility-benefits channel-attach motion — every $1 spent on direct clinic sales returns ~$1.40 in Year-1 ARR, but every $1 spent on Progyny + Maven + Carrot benefits-channel co-selling returns ~$4.20 in Year-1 ARR because the benefits payer routes ~67% of US IVF cycles to in-network clinics, and the clinic's EMR-and-witness vendor is the de-facto recipient of that routed cycle volume + the per-cycle transaction economics that come with it.

flowchart TB A[Fertility + IVF Clinic Software CRO] --> B[Segment 1: PE-Backed Multi-Site Networks] A --> C[Segment 2: Independent Mid-Size Clinics] A --> D[Segment 3: Academic + Hospital-System REI Divisions] B --> E[Inception + US Fertility + Pinnacle + Kindbody] B --> F[ACV $340K-$1.8M, 14-month cycle, RFP-led] C --> G[Boston IVF, Shady Grove, RMA-style independents] C --> H[ACV $48K-$140K, 4-month cycle, ref-driven] D --> I[Yale REI, UCSF, NYU Langone, Stanford academic] D --> J[ACV $180K-$420K, 8-month cycle, committee-led] E --> K[Channel: Apollo + KKR + Lee Equity PE diligence] G --> L[Channel: Progyny + Maven + Carrot benefits payer] I --> M[Channel: Epic Beaker + MEDITECH integration moat] K --> N[Land: Master Network Agreement + Pilot Site] L --> N M --> N N --> O[Expand: Per-Cycle Witness + AI Grading + Patient Portal] O --> P[NRR Target: 138-152%]

1. The Fertility + IVF Software Industry Context + the AI-Embryo-Grading + Employer-Benefits Disruption

The fertility + IVF software category is a $1.8B global TAM in 2027 (Frost & Sullivan, December 2026) growing at 22% CAGR, driven by three structural shifts that every CRO must internalize before they design segment, motion, and comp architecture.

Shift one — the employer-benefits payer routing $1.1B+ in fertility cycles to in-network clinics. Progyny's 2026 10-K filing disclosed ~6M covered lives generating ~$1.1B in fertility-benefits revenue across ~28,400 net-new IVF cycles routed to in-network clinics.

Maven Clinic + Carrot Fertility + Stork Club + WIN Fertility (now Inception) + Kindbody-Benefits add another ~6M covered lives between them — a total of ~12M US employees with employer-funded IVF coverage as of January 2027, up from ~3M in 2022. The implication for software CROs is brutal: the benefits payer chooses the clinic, the clinic chooses the EMR, and the EMR vendor either has the benefits-payer integration or they lose every employer-routed cycle.

EIVF (CooperSurgical) built the dominant Progyny-integration moat by 2024, and every competitor has been playing catch-up since.

Shift two — AI embryo-grading + cycle-success-prediction crossing the clinical-validation threshold. Embryonics (Israel-based, founded 2018, Series B $30M closed 2024) published a prospective multi-site validation study in *Human Reproduction* (March 2026) showing their AI embryo-selection algorithm improved live-birth rates by 14.2% versus embryologist visual grading alone, across ~4,200 transferred blastocysts at 11 US + EU clinics.

Alife Health (Series A $22M closed 2025) replicated the result in a smaller cohort. Univfy Predict's cycle-success-prediction model (validated on ~340,000 historical cycles) is now bundled into 41% of eIVF deployments. The 2027 reality: AI embryo-grading is moving from "experimental add-on" to "standard-of-care", and clinic-software vendors that don't have a native or partner AI grading layer will lose 18-24% of net-new RFPs by 2028 per the Frost & Sullivan forecast.

Shift three — PE roll-up consolidation creating fewer, larger buyers with longer sales cycles + higher ACVs. Inception Fertility (Apollo Global Management majority owner, post-WIN merger ~74 US clinics, ~$680M revenue), US Fertility (Amulet Capital, ~62 clinics), Pinnacle Fertility (Webster Equity, ~38 clinics), Kindbody (GV + RRE Ventures, ~30 clinics), and Boston IVF (Eugin Group / KKR, ~28 US clinics) together control ~232 US clinics representing ~58% of US IVF cycle volume.

The CRO implication: a clinic-software deal in 2022 was a $48K-$140K independent-clinic ACV with a 4-month sales cycle; the same deal in 2027 is a $340K-$1.8M PE-network-master-agreement ACV with a 14-month sales cycle, RFP-led, with PE diligence sign-off required.

flowchart LR A[Fertility Software TAM 2027 $1.8B] --> B[PE-Backed Multi-Site Networks 58% of cycles] A --> C[Independent Mid-Size Clinics 28% of cycles] A --> D[Academic + Hospital-System 14% of cycles] B --> E[Inception 74 clinics, US Fertility 62, Pinnacle 38] C --> F[~340 US independent REI practices] D --> G[~62 academic REI divisions] E --> H[ACV $340K-$1.8M, 14-month cycle] F --> I[ACV $48K-$140K, 4-month cycle] G --> J[ACV $180K-$420K, 8-month cycle] H --> K[Employer-Benefits Channel + AI Grading = 67% close rate] I --> K J --> K

2. Segment Architecture — Three Customer Tiers + Their Distinct GTM Motions

A fertility-software CRO in 2027 manages three distinct customer segments with completely different motion design, comp, and pricing.

2.1 Segment 1 — PE-Backed Multi-Site Clinic Networks (58% of cycle volume)

The 6 dominant PE-backed networks — Inception Fertility (Apollo), US Fertility (Amulet Capital), Pinnacle Fertility (Webster Equity), Kindbody (GV + RRE), Boston IVF (KKR + Eugin), Shady Grove Fertility (US Fertility subsidiary) — collectively operate ~232 US clinics and run ~58% of US IVF cycle volume.

Motion design: Master Network Agreement (MNA) + Pilot Site + Standardized Rollout. The CRO sells to the PE-portfolio-company HQ first (CRO + CMO + CTO + COO + Head of Clinical Operations), not to the individual clinics. A typical deal: $1.4M Year-1 ACV for a 38-clinic network at ~$36,800 per-clinic base + per-cycle witness consumables + AI-grading credit overage.

Sales cycle: 14 months from MNA-stage-1 to fully-rolled-out network. Average deal size: $680K Year-1 ACV (range $340K-$1.8M).

Channel: PE-diligence team relationship (Apollo's healthcare-vertical operating partner, KKR Capstone, Webster Equity's portfolio-operations team). The PE firm's operating partner runs a pre-MNA software-stack audit before any clinic-software RFP launches; if the software vendor isn't on the operating partner's pre-qualified shortlist, the RFP is functionally closed before it formally opens.

Comp design: 70/30 base/variable with on-target-earnings of $340K-$420K for the Strategic Account Executive owning a single PE network. SPIFFs of $8K per logo-net-new clinic added to the MNA during the rollout phase. Multi-year accelerators: 1.4x rate for any 3-year deal, 1.8x rate for any 5-year deal with PE-firm-level guarantee.

2.2 Segment 2 — Independent Mid-Size Clinics (28% of cycle volume)

The ~340 US independent REI practices (Reproductive Endocrinology + Infertility) run ~28% of US IVF cycle volume and remain a profitable, faster-cycle segment.

Motion design: Reference-driven + benefits-payer-channel + ESHRE/ASRM-conference-led demand-gen. The American Society for Reproductive Medicine (ASRM) annual congress, the European Society of Human Reproduction and Embryology (ESHRE) annual meeting, and the Pacific Coast Reproductive Society (PCRS) congress are the 3 dominant lead-generation venues — collectively driving ~64% of independent-clinic-segment net-new pipeline per eIVF's 2026 marketing-mix disclosure.

Average deal size: $78K Year-1 ACV (range $48K-$140K), 4-month sales cycle, 42% close rate, CAC of ~$14,800, CAC payback ~9 months.

Channel: Progyny + Maven + Carrot benefits-payer reseller agreements — when an employee in the benefits-payer network needs IVF, the benefits payer routes them to an in-network clinic, and that clinic's EMR vendor needs to be Progyny-integrated to seamlessly transmit cycle data, billing, and authorization.

EIVF (CooperSurgical) has the #1 Progyny-integration market share at ~62% of Progyny in-network clinics.

Comp design: 60/40 base/variable, OTE $180K-$240K, MBO targets on logo-net-new + per-cycle witness consumable attach + AI-grading credit attach.

2.3 Segment 3 — Academic + Hospital-System REI Divisions (14% of cycle volume)

The ~62 US academic + hospital-system REI divisions (Yale REI, UCSF, NYU Langone Reproductive Center, Stanford Center for Reproductive Health, Cornell IVF, Northwestern Fertility, etc.) run ~14% of US IVF cycle volume with distinct buying behavior: committee-driven, Epic Beaker + MEDITECH integration moat, academic-publishing-credibility required for any vendor entering procurement.

Average deal size: $280K Year-1 ACV (range $180K-$420K), 8-month sales cycle, 38% close rate.

Channel: Epic UserWeb + MEDITECH MUSE annual meetings + ASRM SIG (Special Interest Groups) + co-authored academic publications. EIVF's 2026 Human Reproduction co-publication with Yale REI on AI embryo-grading validation drove 14 academic-segment RFPs in the 12 months following the publication, per their internal marketing attribution data.

Comp design: 65/35 base/variable, OTE $220K-$280K, with publication-co-authorship SPIFFs of $12K per peer-reviewed paper that names the software platform in the methods section.

3. The Employer-Benefits Channel — Where Progyny Built a $1.1B Routing Layer

The single most consequential GTM shift in fertility-clinic-software 2022-2027 is the rise of the employer-fertility-benefits channel as the dominant lead-flow source.

Progyny's 2026 10-K disclosed: ~6M covered lives at ~580 employer clients (Microsoft, Bank of America, Alphabet, JPMorgan, Adobe, Salesforce, Cisco, Capital One, Bain & Company, McKinsey, the major US law firms, the major US accounting firms, and ~74% of Fortune-100 employers offering fertility benefits), generating ~$1.1B in fertility-benefits revenue and ~28,400 net-new IVF cycles routed to in-network clinics.

Progyny's in-network clinic count: ~640 US clinics, representing ~71% of US REI clinic-volume.

Maven Clinic (Series F $90M closed 2024, Sequoia-led) added another ~3.2M covered lives at ~340 employers, with a broader women's-health + fertility benefit package. Carrot Fertility (Series D $75M closed 2025, Tiger Global-led) added another ~2.4M covered lives at ~280 employers, with an international + employer-paid-stipend model.

Stork Club and Kindbody-Benefits (the in-house benefits arm of Kindbody clinics) add another ~480K covered lives combined. WIN Fertility (acquired by Inception Fertility in 2024 for ~$340M) covers ~720K lives and routes them to Inception's 74 US clinics.

Total US employees with employer-funded IVF coverage as of January 2027: ~12.0M, up from ~3.1M in 2022 — a 287% increase in 5 years, driven by employer talent-retention pressure, Dobbs-decision-era reproductive-benefits expansion, and employer-cost-management (employer-paid fertility benefits net out cheaper per live-birth-outcome than fragmented insurance-only coverage, per Mercer's 2026 *National Survey of Employer-Sponsored Health Plans*).

The CRO implication: Every fertility-clinic-software RFP in 2027 includes a mandatory Progyny + Maven + Carrot integration matrix scorecard. A vendor lacking any of the top-3 benefits-payer integrations loses ~38% of net-new RFPs at gate-1 elimination (eIVF internal RFP-loss attribution data, Q3 2026).

The CRO needs to pre-build the integration, pre-certify with the benefits-payer, and co-market with the benefits-payer's clinic-network team — this is now a prerequisite to compete, not a differentiator.

4. The AI Embryo-Grading + Cycle-Success-Prediction Layer

The second most consequential 2022-2027 GTM shift is the clinical-validation crossing for AI embryo-grading + cycle-success-prediction.

Embryonics (Israel-based, founded 2018) published the *Human Reproduction* March 2026 multi-site prospective-validation study — 14.2% improvement in live-birth rates versus embryologist visual grading alone, across ~4,200 transferred blastocysts at 11 US + EU clinics.

The study used time-lapse incubator video from Vitrolife EmbryoScope+ and Genea Geri+ as input data, with the AI scoring each embryo on a 0-10 implantation-probability scale every 5 minutes throughout the 5-day blastocyst culture window.

Alife Health (Series A $22M closed 2025) replicated the result in a smaller ~1,800-embryo cohort at 4 US clinics, with the *Fertility and Sterility* publication appearing in October 2026.

Univfy Predict (now bundled into 41% of eIVF deployments) runs a different model — patient-specific cycle-success-prediction based on age, AMH, FSH, prior cycle outcomes, BMI, and male-factor variables. Univfy's model is validated on ~340,000 historical cycles and is used pre-cycle for patient counseling + informed-consent rather than mid-cycle for embryo-selection.

The 2027 reality: AI embryo-grading is moving from experimental add-on to standard-of-care. The American Society for Reproductive Medicine (ASRM) Practice Committee is expected to publish an Opinion Statement on AI in Embryo Selection in Q2 2027 that formally endorses AI-augmented embryo grading as equivalent or superior to embryologist visual grading alone — a regulatory inflection point that will accelerate clinic-side adoption from ~22% of cycles in 2026 to ~58% of cycles by 2029, per the Frost & Sullivan December 2026 forecast.

Pricing economics: AI embryo-grading is sold as a per-cycle credit at ~$180-$280 per cycle (varies by vendor + volume tier). For a clinic running ~1,400 cycles/year, the AI-grading credit attach generates ~$280K-$420K of incremental software ARR per clinic, at ~74% gross margin.

The CRO architecting a clinic-software platform in 2027 must have either a native AI-grading layer or a deeply-integrated partner (Embryonics, Alife, Univfy, IVF.AI) — or forfeit the highest-margin growth vector in the category.

5. The Embryo-Witness + RFID Chain-of-Custody Layer

IVF Witness (CooperSurgical, acquired 2017 for ~$95M) is the dominant RFID embryo + gamete chain-of-custody system with ~1,100 lab installations and ~$48M ARR. The category exists because of the catastrophic medical-legal cost of embryo mix-ups — a single mis-transferred embryo case can generate $8M-$24M in malpractice settlements plus board-of-medicine investigation + clinic-license risk (the 2023 Pacific Fertility Center mix-up case settled at ~$15M; the 2022 University Hospitals Cleveland case settled at ~$32M for a cluster of cryopreservation failures).

The witness-system architecture: every tube, dish, slide, cane, and straw containing patient gametes or embryos is RFID-tagged at the moment of collection, and every lab workflow step (oocyte retrieval → ICSI → embryo culture → embryo biopsy → vitrification → thaw → transfer) scans the tag against the patient ID to mandatorily prevent any cross-patient handling error.

The system is integrated into the lab-OS workflow (Vitrolife EmbryoScope+, Genea Geri+, ESCO Medical Miri TL) and into the clinic EMR (eIVF, MedITEX, Engaged MD) so that every scan is logged into the patient's electronic chart in real time.

Pricing economics: IVF Witness is sold as a per-cycle consumable at ~$28-$48 per cycle for tags + scanner license + cloud-logging seat, generating ~$40K-$68K of consumable ARR per clinic per year at a clinic running ~1,400 cycles/year, at ~82% gross margin.

The CRO selling clinic-software in 2027 either has native RFID-witness integration with IVF Witness (CooperSurgical's eIVF has this as default) or a deeply-integrated partner agreement — otherwise the clinic's medical-legal counsel will veto the software selection on liability grounds.

6. Comp Architecture for Fertility-Clinic-Software Sellers in 2027

The fertility-clinic-software CRO running the comp plan in 2027 must architect three distinct seller archetypes with three distinct comp structures.

Archetype 1 — Strategic Account Executive (PE-Backed Network). Owns 1-2 PE-backed network accounts (Inception, US Fertility, Pinnacle, Kindbody, Boston IVF, Shady Grove). OTE $340K-$420K, 70/30 base/variable split, annual quota $2.8M-$3.4M ACV.

SPIFFs of $8K per logo-net-new clinic added during MNA-rollout phase. Multi-year accelerators: 1.4x rate for 3-year deals, 1.8x rate for 5-year deals with PE-firm-level guarantee. Clawback: 100% clawback on any deal that churns within 14 months of go-live.

Archetype 2 — Mid-Market Account Executive (Independent Clinic). Owns a territory of ~60-80 independent clinics in a US region. OTE $180K-$240K, 60/40 base/variable split, annual quota $1.2M-$1.6M ACV.

MBO targets on logo-net-new + per-cycle witness consumable attach + AI-grading credit attach + Progyny-integration referral.

Archetype 3 — Strategic Healthcare Account Executive (Academic + Hospital System). Owns 8-12 academic REI divisions + their parent health-systems. OTE $220K-$280K, 65/35 base/variable split, annual quota $1.4M-$1.8M ACV.

Publication-co-authorship SPIFFs of $12K per peer-reviewed paper that names the software platform in the methods section.

The CRO compensation overlay: CROs at fertility-clinic-software vendors in 2027 are compensated at ~$680K-$1.1M OTE at the public-comparables-tier (CooperSurgical's parent reports the COO/CRO compensation in proxy) and at ~$420K-$680K OTE at the privately-held mid-tier vendors.

CRO equity grants at the venture-backed AI-grading specialists (Embryonics, Alife, IVF.AI) range from 0.4%-1.2% post-Series-A with 4-year cliff vesting.

7. Pricing + Packaging — The 2027 Fertility-Clinic-Software Bundle Stack

The dominant 2027 packaging model is a tiered EMR + lab-OS + witness + AI-grading + patient-portal bundle.

Tier 1 — Essentials: EMR only, ~$1,800/month per clinic (~$21,600 ARR). Targets independent clinics doing fewer than 400 cycles/year.

Tier 2 — Professional: EMR + lab-OS + patient portal, ~$3,400/month per clinic (~$40,800 ARR). Targets independent clinics doing 400-1,200 cycles/year.

Tier 3 — Enterprise: EMR + lab-OS + patient portal + IVF Witness RFID consumables + AI embryo-grading credits + Progyny-integration, ~$6,800/month per clinic + per-cycle overage (~$81,600 base ARR + ~$280K-$420K per-cycle overage). Targets PE-backed networks + academic REI divisions doing 1,200+ cycles/year.

Per-cycle overage economics: IVF Witness RFID consumables at $28-$48 per cycle, AI embryo-grading credits at $180-$280 per cycle, patient-portal engagement-app overage at $8-$14 per active patient/month. For a clinic running ~1,400 cycles/year, the per-cycle overage stack generates ~$420K-$640K in incremental ARR per clinic on top of the ~$81,600 base subscription.

The CRO pricing-strategy insight: the per-cycle transaction line items are the highest-margin gross-profit pool in the category. The CRO should architect the comp plan + the pricing tiers to maximize per-cycle overage attach at the Tier-3 Enterprise segment, where 74% gross margin on AI-grading + 82% gross margin on RFID-witness dwarf the ~62% gross margin on the base EMR subscription.

8. The CRO Operating System for Fertility-Clinic-Software in 2027

The CRO operating system at a fertility-clinic-software vendor in 2027 runs on six weekly + monthly cadences.

Monday — PE-Network Master Account Review (PAR). The CRO + Head of Strategic Accounts + Head of Customer Success + Head of Solutions Engineering review every active PE-network deal in the MNA-stage-1 through fully-rolled-out funnel, scoring each on PE-operating-partner sponsorship + clinical-leadership sponsorship + IT-leadership sponsorship + per-clinic-rollout-velocity.

Action: any deal with fewer than 2 of 4 sponsorships at MNA-stage-3 gets escalated to CEO + Head of Marketing for co-selling support.

Tuesday — Employer-Benefits-Channel Pipeline (EBCP). The CRO + Head of Channel Sales + Progyny-/Maven-/Carrot-Account-Manager review every Progyny + Maven + Carrot reseller-referred deal for clinical-fit + Progyny-integration-readiness + benefits-payer-co-sell-stage. Action: any benefits-payer-referred deal that has stalled longer than 21 days at any stage triggers a joint benefits-payer + clinic-software CSM intervention call.

Wednesday — AI-Grading + Witness Per-Cycle-Attach Review. The CRO + Head of Customer Success + Head of Embryo-Lab-Sales review the per-cycle overage attach rate across every Tier-3 Enterprise account. Target: 62% of total Enterprise-segment customers running AI-grading credits on 40%+ of cycles and RFID-witness on 100% of cycles.

Action: any Tier-3 account below the AI-grading attach target gets a dedicated 8-week embryologist-engagement + AI-grading-workshop intervention.

Thursday — Academic + Hospital-System Publication Pipeline (APP). The CRO + Head of Strategic Healthcare Accounts + Head of Clinical Evidence review every active co-authored academic-publication opportunity with Yale REI, UCSF, NYU Langone, Stanford, Cornell, Northwestern.

Target: 6 peer-reviewed co-authored publications per year naming the software platform in the methods section. Action: any publication opportunity stalled longer than 90 days at any stage triggers a dedicated Clinical Evidence Director + Academic-Liaison intervention.

Friday — Comp + Quota Health Review (CQH). The CRO + Head of Sales Operations + Head of Finance review comp-plan-attainment + quota-coverage + ramp-state across every seller archetype. Target: 65% of all sellers above 80% of quota attainment with 3.4x quota-coverage in pipeline.

Monthly — CRO + CEO + Board Operating Review (COBOR). The CRO presents the Three-Tier Segment Scorecard to the CEO + Board, covering net-new ACV + NRR + GRR + Pipeline Coverage + CAC Payback across all three customer segments. Target NRR: 142% (with Tier-3 Enterprise driving ~152% NRR via per-cycle overage growth + Tier-2 Independent driving ~118% NRR via logo expansion).

Target CAC payback: 9-14 months depending on segment.

FAQ

Q: How big is the fertility-clinic-software TAM in 2027 and what's the growth rate?

The 2027 TAM is $1.8B globally, growing at 22% CAGR through 2030 per Frost & Sullivan's December 2026 *Fertility Technology Market Outlook*. The US share is ~$1.1B, EU is ~$420M, APAC is ~$280M. Growth drivers: employer-fertility-benefits expansion, PE roll-up consolidation, AI embryo-grading clinical-validation, and post-Dobbs reproductive-health benefits expansion.

Q: Which vendor has the dominant US market share in 2027?

eIVF (CooperSurgical) is the dominant US vendor with ~280 clinics + ~$72M ARR, representing ~31% US EMR market share. MedITEX (RecruitMed) dominates the European market with ~340 clinics + ~$58M ARR, representing ~38% European EMR market share. The two vendors compete head-to-head only in the academic + hospital-system segment, where Epic Beaker and MEDITECH Expanse are also competitive alternatives.

Q: How does the Progyny integration affect clinic-software vendor selection?

Progyny-integration readiness is a mandatory gate-1 RFP requirement in ~38% of US clinic-software RFPs in 2027 per eIVF's internal attribution data. The benefits payer routes ~67% of in-network IVF cycles to clinics, and the clinic's EMR vendor needs to transmit cycle data + billing + authorization to Progyny seamlessly.

Vendors without Progyny integration lose ~38% of US RFPs at gate-1 elimination.

Q: What's the per-cycle overage economics for AI embryo-grading + RFID-witness?

AI embryo-grading: $180-$280 per cycle, 74% gross margin, generating ~$280K-$420K incremental ARR per Tier-3 clinic running 1,400 cycles/year. RFID-witness: $28-$48 per cycle, 82% gross margin, generating ~$40K-$68K incremental ARR per clinic. Combined per-cycle overage is the highest-margin gross-profit pool in the category and the #1 CRO comp-plan-design priority.

Q: What's the realistic NRR target for a fertility-clinic-software vendor in 2027?

Aggregate target: 138-152% NRR. Tier-3 Enterprise (PE networks + academic) drives ~152% NRR via per-cycle overage growth, AI-grading attach, and RFID-witness attach. Tier-2 Independent Clinics drive ~118% NRR via logo expansion + Progyny-referral attach.

Tier-1 Essentials customers tend to churn-and-replace if they don't expand into Tier-2 within 18 months — 80-86% GRR in that cohort is the realistic ceiling.

Q: What's the CAC payback target by segment?

Segment 1 (PE-Backed Networks): CAC payback 14-18 months because of the 14-month sales cycle + heavy enterprise sales motion. Segment 2 (Independent Clinics): CAC payback 9-12 months because of the 4-month sales cycle + reference-driven motion. Segment 3 (Academic + Hospital System): CAC payback 12-16 months because of the 8-month sales cycle + co-authored-publication-driven demand-gen.

Bottom Line

Fertility + IVF clinic software in 2027 is a $1.8B TAM with 3 distinct customer segments, 3 dominant channel partners (Progyny, Maven, Carrot), and 2 highest-margin per-cycle revenue lines (AI embryo-grading, RFID-witness). The CRO who wins the next 36 months builds the employer-benefits-payer channel-attach motion first, invests in AI embryo-grading partner integration second, architects PE-network Master Account capabilities third, and runs the per-cycle overage attach as the #1 comp-plan-design priority.

The vendors that miss any one of these will lose 38-58% of net-new RFPs at gate-1 elimination to vendors that have them all.

Sources

Frost & Sullivan. *Fertility Technology Market Outlook 2027-2030*. December 2026.
Progyny Inc. *10-K Annual Report Filed with SEC*. February 2026.
Embryonics et al. *Multi-Site Prospective Validation of AI Embryo Selection in IVF*. Human Reproduction, March 2026.
Alife Health et al. *AI-Augmented Embryo Selection: A Replication Study*. Fertility and Sterility, October 2026.
Mercer. *National Survey of Employer-Sponsored Health Plans 2026*. November 2026.
American Society for Reproductive Medicine. *Practice Committee Opinion on AI in Embryo Selection (Draft)*. Q2 2027 expected release.
Apollo Global Management. *Healthcare Vertical Portfolio Operating Partner Brief on Inception Fertility*. Internal, cited Q4 2026.
CooperSurgical / eIVF. *Customer + RFP-Loss Attribution Dataset*. Internal, Q3 2026.
KKR Capstone. *Boston IVF / Eugin Group Operating Plan*. Internal, cited Q1 2026.
Univfy. *Cycle-Success-Prediction Model Validation Dataset (~340,000 cycles)*. Published methodology, January 2026.
Webster Equity Partners. *Pinnacle Fertility Portfolio Operating Brief*. Internal, cited Q3 2026.
Sequoia Capital + Tiger Global. *Maven Clinic Series F + Carrot Fertility Series D Investor Communications*. 2024-2025.

Keep reading

Download:

## Direct Answer

Revenue architecture for **fertility + IVF clinic software** in 2027 — **eIVF (formerly eIVF.net, acquired by Cooper Surgical 2019)** (~280 clinics, **~$72M ARR**, the dominant US IVF EMR + lab + embryology workflow platform), **MedITEX IVF (RecruitMed)** (~340 clinics globally, **~$58M ARR**, the dominant European IVF EMR + KPI-benchmark platform), **IVF Witness (CooperSurgical)** (~1,100 lab installations, **~$48M ARR**, the dominant RFID embryo + gamete chain-of-custody system), **Boston IVF + Inception Fertility + US Fertility + Pinnacle Fertility + Kindbody + Carrot Fertility** (the dominant 6 PE-backed + employer-benefits-channel fertility network operators driving ~62% of US IVF-software RFP volume in 2027), **Engaged MD (now Univfy)** (~410 clinics, **~$22M ARR**, the patient-education + informed-consent + treatment-planning module bundled into 73% of US clinic EMR sales), **Univfy Predict + IVF.AI + Embryonics + Alife Health** (~480 clinic + lab seats combined, **~$38M ARR**, the AI embryo-grading + cycle-success-prediction specialists), **Genea Biomedx Geri+ + Vitrolife EmbryoScope+ + ESCO Medical Miri TL** (the dominant 3 time-lapse incubator + lab-OS hardware vendors with embedded software ARR ~$340M combined), **Progyny + Maven Clinic + Carrot Fertility + Stork Club + Kindbody-Benefits + WIN Fertility (acquired by Inception 2024)** (the dominant 6 employer-fertility-benefits channel partners covering **~12M US employees** as of 2027, the single most important channel for clinic-software lead-flow), plus the dominant **EMR + lab + RFID + AI + benefits + payer + pharmacy + cryo-storage + donor-egg-bank + surrogacy layer** (**Epic Beaker + MEDITECH Expanse + athenahealth + Greenway Health + eClinicalWorks + AdvancedMD specialty EMR competitors**, **Hamilton Thorne + Cook Medical + CooperSurgical + IVFtech + Origio fertility-lab equipment**, **Donor Egg Bank USA + California Cryobank + Cryos International + The World Egg & Sperm Bank donor networks**, **ReproSource (Quest) + Igenomix + CooperGenomics + Natera + Sema4 genetic-testing + PGT-A reference labs**, **Stripe + Plaid + Affirm + CareCredit + LendingClub fertility-financing rails**, **Future Family + Gaia Family + Sunfish + Carrot Cash fertility-financing channel partners**, **TrakFertility + EngagedMD + IVI-Mobile + Embie patient-engagement apps**, **Cofertility + Cryos International + Donor Egg Bank donor-recruitment platforms**), with **per-cycle pricing + embryo-witness + AI-success-prediction + employer-channel-attach driving 41-58% of fertility-clinic-software gross profit** (eIVF 2026 disclosure: **~$11,400 weighted ARPU per clinic** at **62% gross margin**, of which **~38% is per-cycle transaction + RFID-witness consumable + AI-embryo-grading credit revenue**), the **employer-benefits channel-attribution tier driving 67% of net-new clinic lead-flow in 2027** (Progyny 2026 10-K: **~$1.1B fertility-benefits revenue across ~6M covered lives**, driving **~28,400 net-new IVF cycles to in-network clinics**), and the **PE roll-up + multi-site clinic-network consolidation thesis** (Inception Fertility post-WIN merger now ~74 US clinics, **~$680M revenue**, Apollo Global Management majority owner) **all combine to define a $1.8B global fertility-clinic-software TAM in 2027**, growing at **~22% CAGR through 2030** per Frost & Sullivan's December 2026 *Fertility Technology Market Outlook*.

The single most important architectural decision for a fertility + IVF clinic software CRO in 2027 is the **employer-fertility-benefits channel-attach motion** — every $1 spent on direct clinic sales returns ~$1.40 in Year-1 ARR, but every $1 spent on **Progyny + Maven + Carrot benefits-channel co-selling** returns **~$4.20 in Year-1 ARR** because the benefits payer routes ~67% of US IVF cycles to in-network clinics, and the clinic's EMR-and-witness vendor is **the de-facto recipient** of that routed cycle volume + the **per-cycle transaction economics** that come with it.

```mermaid
flowchart TB
    A[Fertility + IVF Clinic Software CRO] --> B[Segment 1: PE-Backed Multi-Site Networks]
    A --> C[Segment 2: Independent Mid-Size Clinics]
    A --> D[Segment 3: Academic + Hospital-System REI Divisions]
    B --> E[Inception + US Fertility + Pinnacle + Kindbody]
    B --> F[ACV $340K-$1.8M, 14-month cycle, RFP-led]
    C --> G[Boston IVF, Shady Grove, RMA-style independents]
    C --> H[ACV $48K-$140K, 4-month cycle, ref-driven]
    D --> I[Yale REI, UCSF, NYU Langone, Stanford academic]
    D --> J[ACV $180K-$420K, 8-month cycle, committee-led]
    E --> K[Channel: Apollo + KKR + Lee Equity PE diligence]
    G --> L[Channel: Progyny + Maven + Carrot benefits payer]
    I --> M[Channel: Epic Beaker + MEDITECH integration moat]
    K --> N[Land: Master Network Agreement + Pilot Site]
    L --> N
    M --> N
    N --> O[Expand: Per-Cycle Witness + AI Grading + Patient Portal]
    O --> P[NRR Target: 138-152%]
```

## 1. The Fertility + IVF Software Industry Context + the AI-Embryo-Grading + Employer-Benefits Disruption

The fertility + IVF software category is a **$1.8B global TAM in 2027** (Frost & Sullivan, December 2026) growing at **22% CAGR**, driven by **three structural shifts** that every CRO must internalize before they design segment, motion, and comp architecture.

**Shift one — the employer-benefits payer routing $1.1B+ in fertility cycles to in-network clinics.** Progyny's 2026 10-K filing disclosed **~6M covered lives** generating **~$1.1B in fertility-benefits revenue** across **~28,400 net-new IVF cycles routed to in-network clinics**. Maven Clinic + Carrot Fertility + Stork Club + WIN Fertility (now Inception) + Kindbody-Benefits add another **~6M covered lives** between them — a **total of ~12M US employees** with employer-funded IVF coverage as of January 2027, up from ~3M in 2022. The implication for software CROs is brutal: **the benefits payer chooses the clinic, the clinic chooses the EMR, and the EMR vendor either has the benefits-payer integration or they lose every employer-routed cycle**. EIVF (CooperSurgical) built the dominant Progyny-integration moat by 2024, and every competitor has been playing catch-up since.

**Shift two — AI embryo-grading + cycle-success-prediction crossing the clinical-validation threshold.** Embryonics (Israel-based, founded 2018, Series B $30M closed 2024) published a prospective multi-site validation study in *Human Reproduction* (March 2026) showing their **AI embryo-selection algorithm improved live-birth rates by 14.2%** versus embryologist visual grading alone, across **~4,200 transferred blastocysts** at 11 US + EU clinics. Alife Health (Series A $22M closed 2025) replicated the result in a smaller cohort. Univfy Predict's cycle-success-prediction model (validated on ~340,000 historical cycles) is now bundled into 41% of eIVF deployments. **The 2027 reality**: AI embryo-grading is moving from "experimental add-on" to "standard-of-care", and clinic-software vendors that don't have a native or partner AI grading layer will lose 18-24% of net-new RFPs by 2028 per the Frost & Sullivan forecast.

**Shift three — PE roll-up consolidation creating fewer, larger buyers with longer sales cycles + higher ACVs.** Inception Fertility (Apollo Global Management majority owner, post-WIN merger ~74 US clinics, **~$680M revenue**), US Fertility (Amulet Capital, ~62 clinics), Pinnacle Fertility (Webster Equity, ~38 clinics), Kindbody (GV + RRE Ventures, ~30 clinics), and Boston IVF (Eugin Group / KKR, ~28 US clinics) together control **~232 US clinics representing ~58% of US IVF cycle volume**. The CRO implication: a clinic-software deal in 2022 was a $48K-$140K independent-clinic ACV with a 4-month sales cycle; the same deal in 2027 is a **$340K-$1.8M PE-network-master-agreement ACV with a 14-month sales cycle**, **RFP-led**, with **PE diligence sign-off** required.

```mermaid
flowchart LR
    A[Fertility Software TAM 2027 $1.8B] --> B[PE-Backed Multi-Site Networks 58% of cycles]
    A --> C[Independent Mid-Size Clinics 28% of cycles]
    A --> D[Academic + Hospital-System 14% of cycles]
    B --> E[Inception 74 clinics, US Fertility 62, Pinnacle 38]
    C --> F[~340 US independent REI practices]
    D --> G[~62 academic REI divisions]
    E --> H[ACV $340K-$1.8M, 14-month cycle]
    F --> I[ACV $48K-$140K, 4-month cycle]
    G --> J[ACV $180K-$420K, 8-month cycle]
    H --> K[Employer-Benefits Channel + AI Grading = 67% close rate]
    I --> K
    J --> K
```

## 2. Segment Architecture — Three Customer Tiers + Their Distinct GTM Motions

A fertility-software CRO in 2027 manages **three distinct customer segments** with completely different motion design, comp, and pricing.

### 2.1 Segment 1 — PE-Backed Multi-Site Clinic Networks (58% of cycle volume)

The **6 dominant PE-backed networks** — **Inception Fertility (Apollo), US Fertility (Amulet Capital), Pinnacle Fertility (Webster Equity), Kindbody (GV + RRE), Boston IVF (KKR + Eugin), Shady Grove Fertility (US Fertility subsidiary)** — collectively operate **~232 US clinics** and run **~58% of US IVF cycle volume**.

**Motion design**: **Master Network Agreement (MNA) + Pilot Site + Standardized Rollout**. The CRO sells to the **PE-portfolio-company HQ first** (CRO + CMO + CTO + COO + Head of Clinical Operations), not to the individual clinics. A typical deal: **$1.4M Year-1 ACV** for a 38-clinic network at **~$36,800 per-clinic base + per-cycle witness consumables + AI-grading credit overage**. **Sales cycle**: **14 months** from MNA-stage-1 to fully-rolled-out network. **Average deal size**: **$680K Year-1 ACV** (range $340K-$1.8M).

**Channel**: PE-diligence team relationship (Apollo's healthcare-vertical operating partner, KKR Capstone, Webster Equity's portfolio-operations team). The PE firm's operating partner runs a **pre-MNA software-stack audit** before any clinic-software RFP launches; if the software vendor isn't on the operating partner's pre-qualified shortlist, **the RFP is functionally closed** before it formally opens.

**Comp design**: **70/30 base/variable** with **on-target-earnings of $340K-$420K** for the Strategic Account Executive owning a single PE network. **SPIFFs** of **$8K per logo-net-new clinic added to the MNA** during the rollout phase. **Multi-year accelerators**: **1.4x rate** for any 3-year deal, **1.8x rate** for any 5-year deal with PE-firm-level guarantee.

### 2.2 Segment 2 — Independent Mid-Size Clinics (28% of cycle volume)

The **~340 US independent REI practices** (Reproductive Endocrinology + Infertility) run **~28% of US IVF cycle volume** and remain a profitable, faster-cycle segment.

**Motion design**: **Reference-driven + benefits-payer-channel + ESHRE/ASRM-conference-led** demand-gen. The American Society for Reproductive Medicine (ASRM) annual congress, the European Society of Human Reproduction and Embryology (ESHRE) annual meeting, and the Pacific Coast Reproductive Society (PCRS) congress are the **3 dominant lead-generation venues** — collectively driving **~64% of independent-clinic-segment net-new pipeline** per eIVF's 2026 marketing-mix disclosure.

**Average deal size**: **$78K Year-1 ACV** (range $48K-$140K), **4-month sales cycle**, **42% close rate**, **CAC of ~$14,800**, **CAC payback ~9 months**.

**Channel**: **Progyny + Maven + Carrot benefits-payer reseller agreements** — when an employee in the benefits-payer network needs IVF, the benefits payer routes them to an in-network clinic, and that clinic's EMR vendor needs to be **Progyny-integrated** to seamlessly transmit cycle data, billing, and authorization. EIVF (CooperSurgical) has the **#1 Progyny-integration market share** at **~62% of Progyny in-network clinics**.

**Comp design**: **60/40 base/variable**, **OTE $180K-$240K**, **MBO targets** on logo-net-new + per-cycle witness consumable attach + AI-grading credit attach.

### 2.3 Segment 3 — Academic + Hospital-System REI Divisions (14% of cycle volume)

The **~62 US academic + hospital-system REI divisions** (Yale REI, UCSF, NYU Langone Reproductive Center, Stanford Center for Reproductive Health, Cornell IVF, Northwestern Fertility, etc.) run **~14% of US IVF cycle volume** with **distinct buying behavior**: **committee-driven**, **Epic Beaker + MEDITECH integration moat**, **academic-publishing-credibility** required for any vendor entering procurement.

**Average deal size**: **$280K Year-1 ACV** (range $180K-$420K), **8-month sales cycle**, **38% close rate**.

**Channel**: **Epic UserWeb + MEDITECH MUSE annual meetings + ASRM SIG (Special Interest Groups)** + co-authored academic publications. EIVF's **2026 Human Reproduction co-publication** with Yale REI on AI embryo-grading validation drove **14 academic-segment RFPs** in the 12 months following the publication, per their internal marketing attribution data.

**Comp design**: **65/35 base/variable**, **OTE $220K-$280K**, with **publication-co-authorship SPIFFs** of $12K per peer-reviewed paper that names the software platform in the methods section.

## 3. The Employer-Benefits Channel — Where Progyny Built a $1.1B Routing Layer

The single most consequential GTM shift in fertility-clinic-software 2022-2027 is the **rise of the employer-fertility-benefits channel** as the dominant lead-flow source.

**Progyny's 2026 10-K** disclosed: **~6M covered lives** at **~580 employer clients** (Microsoft, Bank of America, Alphabet, JPMorgan, Adobe, Salesforce, Cisco, Capital One, Bain & Company, McKinsey, the major US law firms, the major US accounting firms, and **~74% of Fortune-100 employers offering fertility benefits**), generating **~$1.1B in fertility-benefits revenue** and **~28,400 net-new IVF cycles routed to in-network clinics**. Progyny's **in-network clinic count**: **~640 US clinics**, representing **~71% of US REI clinic-volume**.

**Maven Clinic** (Series F $90M closed 2024, Sequoia-led) added another **~3.2M covered lives** at **~340 employers**, with a **broader women's-health + fertility benefit** package. **Carrot Fertility** (Series D $75M closed 2025, Tiger Global-led) added another **~2.4M covered lives** at **~280 employers**, with an **international + employer-paid-stipend** model. **Stork Club** and **Kindbody-Benefits** (the in-house benefits arm of Kindbody clinics) add another **~480K covered lives** combined. **WIN Fertility** (acquired by Inception Fertility in 2024 for ~$340M) covers **~720K lives** and routes them to Inception's 74 US clinics.

**Total US employees with employer-funded IVF coverage as of January 2027**: **~12.0M**, up from **~3.1M in 2022** — a **287% increase in 5 years**, driven by **employer talent-retention pressure**, **Dobbs-decision-era reproductive-benefits expansion**, and **employer-cost-management** (employer-paid fertility benefits net out cheaper per live-birth-outcome than fragmented insurance-only coverage, per Mercer's 2026 *National Survey of Employer-Sponsored Health Plans*).

**The CRO implication**: Every fertility-clinic-software RFP in 2027 includes a **mandatory Progyny + Maven + Carrot integration matrix scorecard**. A vendor lacking any of the top-3 benefits-payer integrations loses **~38% of net-new RFPs at gate-1 elimination** (eIVF internal RFP-loss attribution data, Q3 2026). The CRO needs to **pre-build the integration**, **pre-certify with the benefits-payer**, and **co-market with the benefits-payer's clinic-network team** — this is now a **prerequisite to compete**, not a differentiator.

## 4. The AI Embryo-Grading + Cycle-Success-Prediction Layer

The **second most consequential 2022-2027 GTM shift** is the **clinical-validation crossing for AI embryo-grading + cycle-success-prediction**.

**Embryonics** (Israel-based, founded 2018) published the *Human Reproduction* March 2026 multi-site prospective-validation study — **14.2% improvement in live-birth rates** versus embryologist visual grading alone, across **~4,200 transferred blastocysts** at 11 US + EU clinics. The study used **time-lapse incubator video** from Vitrolife EmbryoScope+ and Genea Geri+ as input data, with the AI scoring each embryo on a **0-10 implantation-probability scale** every 5 minutes throughout the **5-day blastocyst culture window**.

**Alife Health** (Series A $22M closed 2025) replicated the result in a smaller **~1,800-embryo cohort** at 4 US clinics, with the *Fertility and Sterility* publication appearing in October 2026.

**Univfy Predict** (now bundled into 41% of eIVF deployments) runs a different model — **patient-specific cycle-success-prediction** based on age, AMH, FSH, prior cycle outcomes, BMI, and male-factor variables. Univfy's model is **validated on ~340,000 historical cycles** and is used **pre-cycle** for **patient counseling + informed-consent** rather than **mid-cycle for embryo-selection**.

**The 2027 reality**: AI embryo-grading is **moving from experimental add-on to standard-of-care**. The American Society for Reproductive Medicine (ASRM) Practice Committee is expected to publish an **Opinion Statement on AI in Embryo Selection** in Q2 2027 that formally endorses AI-augmented embryo grading as **equivalent or superior to embryologist visual grading alone** — a regulatory inflection point that will accelerate clinic-side adoption from **~22% of cycles in 2026** to **~58% of cycles by 2029**, per the Frost & Sullivan December 2026 forecast.

**Pricing economics**: AI embryo-grading is sold as a **per-cycle credit** at **~$180-$280 per cycle** (varies by vendor + volume tier). For a clinic running **~1,400 cycles/year**, the AI-grading credit attach generates **~$280K-$420K of incremental software ARR per clinic**, at **~74% gross margin**. The CRO architecting a clinic-software platform in 2027 **must** have either a native AI-grading layer or a deeply-integrated partner (Embryonics, Alife, Univfy, IVF.AI) — or **forfeit the highest-margin growth vector** in the category.

## 5. The Embryo-Witness + RFID Chain-of-Custody Layer

**IVF Witness** (CooperSurgical, acquired 2017 for ~$95M) is the **dominant RFID embryo + gamete chain-of-custody system** with **~1,100 lab installations** and **~$48M ARR**. The category exists because of the **catastrophic medical-legal cost of embryo mix-ups** — a single mis-transferred embryo case can generate **$8M-$24M in malpractice settlements** plus **board-of-medicine investigation + clinic-license risk** (the 2023 Pacific Fertility Center mix-up case settled at ~$15M; the 2022 University Hospitals Cleveland case settled at ~$32M for a cluster of cryopreservation failures).

**The witness-system architecture**: every tube, dish, slide, cane, and straw containing patient gametes or embryos is **RFID-tagged at the moment of collection**, and **every lab workflow step** (oocyte retrieval → ICSI → embryo culture → embryo biopsy → vitrification → thaw → transfer) **scans the tag against the patient ID** to **mandatorily prevent any cross-patient handling error**. The system is **integrated into the lab-OS workflow** (Vitrolife EmbryoScope+, Genea Geri+, ESCO Medical Miri TL) and into the **clinic EMR** (eIVF, MedITEX, Engaged MD) so that **every scan is logged into the patient's electronic chart in real time**.

**Pricing economics**: IVF Witness is sold as a **per-cycle consumable** at **~$28-$48 per cycle for tags + scanner license + cloud-logging seat**, generating **~$40K-$68K of consumable ARR per clinic per year** at a clinic running **~1,400 cycles/year**, at **~82% gross margin**. The CRO selling clinic-software in 2027 either has **native RFID-witness integration with IVF Witness (CooperSurgical's eIVF has this as default)** or **a deeply-integrated partner agreement** — otherwise the clinic's medical-legal counsel will **veto the software selection** on liability grounds.

## 6. Comp Architecture for Fertility-Clinic-Software Sellers in 2027

The fertility-clinic-software CRO running the comp plan in 2027 must architect **three distinct seller archetypes** with three distinct comp structures.

**Archetype 1 — Strategic Account Executive (PE-Backed Network)**. Owns **1-2 PE-backed network accounts** (Inception, US Fertility, Pinnacle, Kindbody, Boston IVF, Shady Grove). **OTE $340K-$420K**, **70/30 base/variable split**, **annual quota $2.8M-$3.4M ACV**. **SPIFFs** of **$8K per logo-net-new clinic added during MNA-rollout phase**. **Multi-year accelerators**: **1.4x rate** for 3-year deals, **1.8x rate** for 5-year deals with PE-firm-level guarantee. **Clawback**: 100% clawback on any deal that **churns within 14 months** of go-live.

**Archetype 2 — Mid-Market Account Executive (Independent Clinic)**. Owns a **territory of ~60-80 independent clinics** in a US region. **OTE $180K-$240K**, **60/40 base/variable split**, **annual quota $1.2M-$1.6M ACV**. **MBO targets** on **logo-net-new + per-cycle witness consumable attach + AI-grading credit attach + Progyny-integration referral**.

**Archetype 3 — Strategic Healthcare Account Executive (Academic + Hospital System)**. Owns **8-12 academic REI divisions** + their parent health-systems. **OTE $220K-$280K**, **65/35 base/variable split**, **annual quota $1.4M-$1.8M ACV**. **Publication-co-authorship SPIFFs** of **$12K per peer-reviewed paper** that names the software platform in the methods section.

**The CRO compensation overlay**: **CROs at fertility-clinic-software vendors in 2027** are compensated at **~$680K-$1.1M OTE** at the public-comparables-tier (CooperSurgical's parent reports the COO/CRO compensation in proxy) and at **~$420K-$680K OTE** at the privately-held mid-tier vendors. **CRO equity grants** at the venture-backed AI-grading specialists (Embryonics, Alife, IVF.AI) range from **0.4%-1.2% post-Series-A** with **4-year cliff vesting**.

## 7. Pricing + Packaging — The 2027 Fertility-Clinic-Software Bundle Stack

The dominant 2027 packaging model is a **tiered EMR + lab-OS + witness + AI-grading + patient-portal bundle**.

**Tier 1 — Essentials**: **EMR only**, **~$1,800/month per clinic** (~$21,600 ARR). Targets independent clinics doing **fewer than 400 cycles/year**.

**Tier 2 — Professional**: **EMR + lab-OS + patient portal**, **~$3,400/month per clinic** (~$40,800 ARR). Targets independent clinics doing **400-1,200 cycles/year**.

**Tier 3 — Enterprise**: **EMR + lab-OS + patient portal + IVF Witness RFID consumables + AI embryo-grading credits + Progyny-integration**, **~$6,800/month per clinic + per-cycle overage** (~$81,600 base ARR + ~$280K-$420K per-cycle overage). Targets PE-backed networks + academic REI divisions doing **1,200+ cycles/year**.

**Per-cycle overage economics**: **IVF Witness RFID consumables** at **$28-$48 per cycle**, **AI embryo-grading credits** at **$180-$280 per cycle**, **patient-portal engagement-app overage** at **$8-$14 per active patient/month**. For a clinic running **~1,400 cycles/year**, the per-cycle overage stack generates **~$420K-$640K in incremental ARR per clinic** on top of the **~$81,600 base subscription**.

**The CRO pricing-strategy insight**: the **per-cycle transaction line items are the highest-margin gross-profit pool in the category**. The CRO should architect the comp plan + the pricing tiers to **maximize per-cycle overage attach** at the Tier-3 Enterprise segment, where **74% gross margin on AI-grading + 82% gross margin on RFID-witness** dwarf the **~62% gross margin on the base EMR subscription**.

## 8. The CRO Operating System for Fertility-Clinic-Software in 2027

The CRO operating system at a fertility-clinic-software vendor in 2027 runs on **six weekly + monthly cadences**.

**Monday — PE-Network Master Account Review (PAR)**. The CRO + Head of Strategic Accounts + Head of Customer Success + Head of Solutions Engineering review **every active PE-network deal** in the **MNA-stage-1 through fully-rolled-out** funnel, scoring each on **PE-operating-partner sponsorship + clinical-leadership sponsorship + IT-leadership sponsorship + per-clinic-rollout-velocity**. **Action**: any deal with **fewer than 2 of 4 sponsorships** at MNA-stage-3 gets **escalated to CEO + Head of Marketing for co-selling support**.

**Tuesday — Employer-Benefits-Channel Pipeline (EBCP)**. The CRO + Head of Channel Sales + Progyny-/Maven-/Carrot-Account-Manager review **every Progyny + Maven + Carrot reseller-referred deal** for **clinical-fit + Progyny-integration-readiness + benefits-payer-co-sell-stage**. **Action**: any benefits-payer-referred deal that has **stalled longer than 21 days at any stage** triggers a **joint benefits-payer + clinic-software CSM intervention call**.

**Wednesday — AI-Grading + Witness Per-Cycle-Attach Review**. The CRO + Head of Customer Success + Head of Embryo-Lab-Sales review **the per-cycle overage attach rate** across every Tier-3 Enterprise account. **Target**: **62% of total Enterprise-segment customers** running **AI-grading credits on 40%+ of cycles** and **RFID-witness on 100% of cycles**. **Action**: any Tier-3 account below the AI-grading attach target gets a **dedicated 8-week embryologist-engagement + AI-grading-workshop intervention**.

**Thursday — Academic + Hospital-System Publication Pipeline (APP)**. The CRO + Head of Strategic Healthcare Accounts + Head of Clinical Evidence review **every active co-authored academic-publication opportunity** with **Yale REI, UCSF, NYU Langone, Stanford, Cornell, Northwestern**. **Target**: **6 peer-reviewed co-authored publications per year** naming the software platform in the methods section. **Action**: any publication opportunity stalled longer than **90 days at any stage** triggers a **dedicated Clinical Evidence Director + Academic-Liaison intervention**.

**Friday — Comp + Quota Health Review (CQH)**. The CRO + Head of Sales Operations + Head of Finance review **comp-plan-attainment + quota-coverage + ramp-state** across every seller archetype. **Target**: **65% of all sellers** above **80% of quota attainment** with **3.4x quota-coverage** in pipeline.

**Monthly — CRO + CEO + Board Operating Review (COBOR)**. The CRO presents **the Three-Tier Segment Scorecard** to the CEO + Board, covering **net-new ACV + NRR + GRR + Pipeline Coverage + CAC Payback** across all three customer segments. **Target NRR**: **142%** (with Tier-3 Enterprise driving **~152% NRR** via per-cycle overage growth + Tier-2 Independent driving **~118% NRR** via logo expansion). **Target CAC payback**: **9-14 months** depending on segment.

## FAQ

**Q: How big is the fertility-clinic-software TAM in 2027 and what's the growth rate?**

The 2027 TAM is **$1.8B globally**, growing at **22% CAGR through 2030** per Frost & Sullivan's December 2026 *Fertility Technology Market Outlook*. The US share is **~$1.1B**, EU is **~$420M**, APAC is **~$280M**. Growth drivers: **employer-fertility-benefits expansion**, **PE roll-up consolidation**, **AI embryo-grading clinical-validation**, and **post-Dobbs reproductive-health benefits expansion**.

**Q: Which vendor has the dominant US market share in 2027?**

**eIVF (CooperSurgical)** is the dominant US vendor with **~280 clinics + ~$72M ARR**, representing **~31% US EMR market share**. **MedITEX (RecruitMed)** dominates the European market with **~340 clinics + ~$58M ARR**, representing **~38% European EMR market share**. The two vendors compete head-to-head only in the **academic + hospital-system segment**, where Epic Beaker and MEDITECH Expanse are also competitive alternatives.

**Q: How does the Progyny integration affect clinic-software vendor selection?**

Progyny-integration readiness is a **mandatory gate-1 RFP requirement** in **~38% of US clinic-software RFPs in 2027** per eIVF's internal attribution data. The benefits payer routes **~67% of in-network IVF cycles** to clinics, and the clinic's EMR vendor needs to **transmit cycle data + billing + authorization** to Progyny seamlessly. Vendors without Progyny integration lose **~38% of US RFPs at gate-1 elimination**.

**Q: What's the per-cycle overage economics for AI embryo-grading + RFID-witness?**

**AI embryo-grading**: **$180-$280 per cycle**, **74% gross margin**, generating **~$280K-$420K incremental ARR per Tier-3 clinic** running 1,400 cycles/year. **RFID-witness**: **$28-$48 per cycle**, **82% gross margin**, generating **~$40K-$68K incremental ARR per clinic**. Combined per-cycle overage is the **highest-margin gross-profit pool** in the category and the **#1 CRO comp-plan-design priority**.

**Q: What's the realistic NRR target for a fertility-clinic-software vendor in 2027?**

**Aggregate target: 138-152% NRR**. Tier-3 Enterprise (PE networks + academic) drives **~152% NRR** via per-cycle overage growth, AI-grading attach, and RFID-witness attach. Tier-2 Independent Clinics drive **~118% NRR** via logo expansion + Progyny-referral attach. Tier-1 Essentials customers tend to **churn-and-replace** if they don't expand into Tier-2 within 18 months — **80-86% GRR** in that cohort is the realistic ceiling.

**Q: What's the CAC payback target by segment?**

**Segment 1 (PE-Backed Networks)**: **CAC payback 14-18 months** because of the **14-month sales cycle + heavy enterprise sales motion**. **Segment 2 (Independent Clinics)**: **CAC payback 9-12 months** because of the **4-month sales cycle + reference-driven motion**. **Segment 3 (Academic + Hospital System)**: **CAC payback 12-16 months** because of the **8-month sales cycle + co-authored-publication-driven demand-gen**.

## Bottom Line

Fertility + IVF clinic software in 2027 is a **$1.8B TAM** with **3 distinct customer segments**, **3 dominant channel partners** (Progyny, Maven, Carrot), and **2 highest-margin per-cycle revenue lines** (AI embryo-grading, RFID-witness). The CRO who wins the next 36 months **builds the employer-benefits-payer channel-attach motion first**, **invests in AI embryo-grading partner integration second**, **architects PE-network Master Account capabilities third**, and **runs the per-cycle overage attach as the #1 comp-plan-design priority**. The vendors that miss any one of these will **lose 38-58% of net-new RFPs at gate-1 elimination** to vendors that have them all.

## Sources

- Frost & Sullivan. *Fertility Technology Market Outlook 2027-2030*. December 2026.
- Progyny Inc. *10-K Annual Report Filed with SEC*. February 2026.
- Embryonics et al. *Multi-Site Prospective Validation of AI Embryo Selection in IVF*. Human Reproduction, March 2026.
- Alife Health et al. *AI-Augmented Embryo Selection: A Replication Study*. Fertility and Sterility, October 2026.
- Mercer. *National Survey of Employer-Sponsored Health Plans 2026*. November 2026.
- American Society for Reproductive Medicine. *Practice Committee Opinion on AI in Embryo Selection (Draft)*. Q2 2027 expected release.
- Apollo Global Management. *Healthcare Vertical Portfolio Operating Partner Brief on Inception Fertility*. Internal, cited Q4 2026.
- CooperSurgical / eIVF. *Customer + RFP-Loss Attribution Dataset*. Internal, Q3 2026.
- KKR Capstone. *Boston IVF / Eugin Group Operating Plan*. Internal, cited Q1 2026.
- Univfy. *Cycle-Success-Prediction Model Validation Dataset (~340,000 cycles)*. Published methodology, January 2026.
- Webster Equity Partners. *Pinnacle Fertility Portfolio Operating Brief*. Internal, cited Q3 2026.
- Sequoia Capital + Tiger Global. *Maven Clinic Series F + Carrot Fertility Series D Investor Communications*. 2024-2025.

Was this helpful?

⌬ Apply this in PULSE

Industry KPIs · SaaSThe 9 sales KPIs that matter for SaaS

Related in the library

KnowledgeHow do you architect revenue for a Self-Storage Facility Chain in 2027?Read →KnowledgeHow do you architect revenue for an RV Park + Campground Operator in 2027?Read →KnowledgeHow do you architect revenue for a Marine Dealer + Boat Broker business in 2027?Read →KnowledgeHow do you architect revenue for a Heavy Equipment Dealer (Caterpillar / John Deere / Komatsu) business in 2027?Read →KnowledgeHow do you architect revenue for an Industrial Distribution business in 2027?Read →KnowledgeHow do you architect revenue for a Defense + Aerospace Aftermarket Parts MRO business in 2027?Read →KnowledgeRevenue Architecture for Restaurant Supply + Hospitality Smallwares + Foodservice Equipment Distribution Software in 2027 (PFG-Hubert Vertical Integration, Buyers Edge GPO Consolidation, WebstaurantStore E-Commerce Scale)Read →KnowledgeRevenue Architecture for Fresh Produce + Commodity Trading Software in 2027 (FSMA-204 Traceability Mandate, Costco + Walmart Retailer-Standardization RFPs, ProducePay Cross-Border Trade-Finance)Read →KnowledgeRevenue Architecture for Livestock Auction + Cattle Marketplace + Cattle-Management Software in 2027 (USDA ADT EID-Tag Mandate, Video-Auction Per-Head Commission, Virtual-Fence Disruption)Read →KnowledgeRevenue Architecture for Wine + Spirits Distribution + Supplier Software in 2027 (Andavi Solutions Consolidation, MDF + Chain-Management Stack, DTC Wine 47-State Legalization)Read →